kallikrein related peptidase 13Genealiases: KLK-L4 · KLKL4
Q-omics provides the consensus-scored KLK13 profile across patient tissues and cancer cell-line models. KLK13 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KLK13 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, KLK13 RNA expression shows 14,040 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, HNSC, and THYM as cancer lineages where KLK13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLK13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLK13 survival associations across molecular data types. KLK13 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLK13 RNA expression–survival associations across cancer types. High KLK13 expression shows unfavorable associations in SKCM, KIRC, LGG and UCS, but favorable associations in UVM and MESO. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for KLK13 RNA expression.
This table summarizes KLK13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KLK13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLK13 shows lower tumor expression in HNSC, COAD and BRCA and higher tumor expression in THCA, KIRC and LUSC. The HNSC box plot shows higher KLK13 RNA expression in normal versus tumor tissue (log2 FC = −2.989, t-test p < 0.001).
This table shows molecular features associated with KLK13 in patient tissues and cancer cell lines. In patient samples, KLK13 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLK13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
